Ten Years of Cardihab: A Celebration of Shared Purpose
In February 2016, Cardihab Pty Ltd was incorporated in Brisbane, Queensland. At the time, the company's digital cardiac rehabilitation platform existed as a research prototype - the product of years of rigorous scientific work and clinical trials. The question was not whether the technology concept worked. The evidence showed it did. The two main questions were:
1. Whether the academic concept and research could be translated into the commercial grade solution that would withstand customer, user expectations, and excel in a risk averse, slow moving and demanding ecosystem entrenched in conventional in person models of care.
2. What would it take to transform it into a nationally deployed digital therapeutic that solves the problem of access to care
Ten years later, we know the answers.
The Problem That Started It All
To understand what Cardihab set out to do, it helps to understand the scale of the challenge it was built to address. Cardiac rehabilitation is one of the most comprehensively evidenced interventions in preventive cardiology. It reduces the risk of repeat cardiac events, cuts unplanned hospital readmissions and improves quality of life for patients recovering from heart attacks, cardiac procedures and heart failure.
The evidence is not equivocal - it is overwhelming.
And yet, by most estimates, fewer than one in five eligible patients in Australia and comparable health systems complete a cardiac rehabilitation program. The barriers are practical and pervasive: geography, transport, time, work commitments, cultural factors, and the design of traditional programs that require repeated clinic attendance at a time when patients are often fragile, fatigued, and anxious.
Cardihab's founding premise was that digital technology - specifically, a clinically rigorous, guideline-aligned platform delivered through a smartphone and a clinician portal - could dismantle these barriers without compromising clinical standards.
A Mission That Required a Village
What distinguishes the story of Cardihab's first decade is not a single breakthrough or a single benefactor. It is the diversity and depth of the collaborations that made sustained progress possible.
Scientific and research partnerships established the evidence foundation and have continued to generate peer-reviewed clinical data published in leading cardiovascular journals. Without this evidence, we would have had technology. With it, we have a digital therapeutic that clinicians can trust, and health systems can adopt.
Investment from a range of venture capital funds, angel networks, strategic investors and people who invest in impact initiatives, that provided the capital runway that allowed a small Australian company to build a platform to medical-device standards - long before revenue could fund that work independently. Healthcare startups are capital-intensive and slow to scale; the investors who backed Cardihab and supported us along this journey have been our lifeline.
Government grant programs and public health innovation program funds recognised that supporting evidence-based digital health companies serves a legitimate public interest - reducing preventable hospitalisations, improving equitable access to care and building a domestic health technology industry. Non-dilutive support at critical growth stages made a material difference to what Cardihab could build and when. The R&D Tax incentive too has been critical to ensure the ongoing development and research into our platform is achievable.
Clinicians and healthcare providers were, and remain, indispensable. A digital therapeutic has no value if it cannot be integrated into real clinical workflows and trusted by real practitioners. The feedback, clinical input and implementation experience of healthcare partners across Australia - in hospitals, specialist practices, health services, virtual care services and health insurance prevention programs shaped every iteration of the Cardihab platform.
Through demonstrated real world impact, our private health insurance and public healthcare partnerships are opening pathways to access and scale that would otherwise have been impossible, due to the absence of funding and reimbursement for digital therapeutics in Australia. By embedding digital cardiac rehabilitation into health fund benefits and insurer-supported programs, Cardihab has been able to reach patients who might never have received a traditional referral, or who might otherwise end up on an extensive wait list for scarce in person care.
Research collaborations with academic and clinical research organisations have extended the evidence base beyond the founding randomised controlled trial - into real-world cardiology settings, into hospital admission data, and into emerging areas like heart failure. This ongoing evidence of generation is what sustains clinical credibility over time.
Accelerator and ecosystem programs -from early-stage startup programs through to national digital health commercialisation initiatives - provided infrastructure, mentorship and access to networks that an early-stage company cannot build independently. The Australian health technology innovation ecosystem, though challenging to navigate, has matured significantly over the past decade, and Cardihab has both benefited from and contributed to that maturation.
Technology and infrastructure partners provide the cloud, security, and compliance foundations on which a medical-grade platform must be built.
The Patients
Above all other stakeholders, the patients who have used Cardihab's programs over the past decade represent both the purpose and the proof of the work. Every person who has completed a digital cardiac rehabilitation, heart failure or primary prevention program at home - who has logged an exercise session, tracked their medications, engaged with their clinician through a video call, and finished a program they might otherwise have abandoned - is a data point in the case for digital therapeutics. And more than a data point: a person who is living better because of access to care that met them where they were.
Looking Ahead
Cardihab enters its second decade as a TGA-registered Class Ila medical device - the highest regulatory designation held by any digital cardiac rehabilitation platform in Australia - with ISO 13485 quality management certification and ISO 27001 information security certification. Our clinical evidence base spans peer-reviewed publications in leading cardiovascular journals. Our platform is deployed across Australia with major health insurers, hospital health services and specialist clinical networks.
The opportunity ahead is larger than the achievement behind. Cardiovascular disease remains the world's leading cause of death. The participation gap in cardiac rehabilitation remains stubbornly wide. And the technologies available to close that gap are more capable than ever.
To every collaborator who has been part of the first ten years: thank you. The second decade begins now.